Sarcoma | Clinical

Ripretinib Stills Holds a Place in the Advanced GIST Landscape After INTRIGUE Study

January 25, 2022

Results presented during the 2022 January ASCO Plenary Series showed that ripretinib did perform better than sunitinib in terms of the objective response rate, and the safety profile of the drug was favorable compared with sunitinib.